Valuation : Ionis Pharmaceuticals, Inc.

Market Cap 9.95B 8.58B 8.07B 7.36B 13.83B 944B 13.91B 95.46B 37.15B 480B 37.36B 36.55B 1,593B P/E 2026 *
-16.4x
P/E 2027 * -31.7x
Enterprise Value 9.85B 8.5B 7.99B 7.28B 13.69B 935B 13.76B 94.47B 36.77B 475B 36.97B 36.17B 1,576B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 7.14x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-0.80%
1 week-5.80%
Current month-0.80%
1 month+15.67%
3 months-20.56%
6 months-26.21%
Current year-24.31%
1 week 59.7
Extreme 59.7
63.48
1 month 52.16
Extreme 52.165
64.19
Current year 50
Extreme 50.005
86.74
1 year 50
Extreme 50.005
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 A Buy

Director

5,000 0.0030%
7/15/26 A Free

Director

3,399 0.0021%
7/15/26 A Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-5.80%+40.45%+47.85% 9.95B
+0.81%-0.92%+3.34%+17.59% 49.74B
+2.09%-0.71%+452.73%+498.77% 44.98B
-1.09%-0.41%+35.40%+15.17% 42.52B
-0.26%-4.71%+17.19%+71.67% 40.78B
-0.48%-0.84%+16.25%+49.80% 32.89B
-1.06%+2.87% - - 17.09B
-1.81%-5.02%+22.65%+113.24% 16.28B
+0.31%-1.48%+16.84%+26.26% 14.4B
-2.05%-5.14%+72.89%+34.69% 13.48B
Average -0.61%-2.78%+75.30%+97.23% 28.21B
Weighted average by Cap. -0.33%-2.39%+95.34%+119.54%

Financials

2026 *2027 *
Net sales 913M 788M 741M 675M 1.27B 86.69B 1.28B 8.76B 3.41B 44.1B 3.43B 3.35B 146B 1.4B 1.21B 1.14B 1.04B 1.95B 133B 1.96B 13.45B 5.23B 67.68B 5.26B 5.15B 224B
Net income -602M -520M -489M -445M -837M -57.17B -842M -5.78B -2.25B -29.08B -2.26B -2.21B -96.44B -326M -281M -264M -241M -453M -30.93B -455M -3.13B -1.22B -15.73B -1.22B -1.2B -52.16B
Net Debt -103M -88.82M -83.55M -76.11M -143M -9.77B -144M -988M -384M -4.97B -387M -378M -16.48B 57.45M 49.56M 46.62M 42.47M 79.87M 5.45B 80.3M 551M 215M 2.77B 216M 211M 9.2B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
01/09/26 $59.88 -0.80% 1,872,594
31/08/26 $60.36 -1.13% 2,017,160
28/08/26 $61.05 -2.21% 1,850,852
27/08/26 $62.43 -1.47% 1,625,581
26/08/26 $63.36 -0.33% 2,152,847
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
59.88USD
Average target price
88.00USD
Spread / Average Target
+46.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock